Incretin physiology and its role in type 2 diabetes mellitus

Journal of the American Osteopathic Association

Volumn 110, Issue 7 SUPPL. 7, 2010, Pages

  Svec, Frank ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; LIRAGLUTIDE; PEPTIDE; PYRAZINE DERIVATIVE; SAXAGLIPTIN; SITAGLIPTIN; TRIAZOLE DERIVATIVE; VENOM;

BIOSYNTHESIS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; PEPTIDES; PYRAZINES; TRIAZOLES; VENOMS;

EID: 77957232105     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492-498.
2. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143 (11):4397-4408. http://endo.endojournals.org/cgi/content/full/143/11/4397. Accessed July 1, 2010.
3. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-744.
4. Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220-224. http://jcem.endojournals.org/cgi/content/full/88/1/220. Accessed July 1, 2010.
5. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005 [published online ahead of print January 14, 2006]. Diabetologia. 2006;49(2):253-260.
6. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med. 1970;283(3):109-115.
7. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082-3089. http://jcem.endojournals.org/cgi/content/full/88/7/3082. Accessed July 1, 2010.
8. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38 (4):665-673.
9. Zander M, Madsbad S, Madsen J, Holst JJ. Effect of 6-week course of glucagon-like peptide on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824-830.
10. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100. http://care.diabetesjournals.org/content/28/5/1092.long. Accessed July 1, 2010.
11. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11): 2628-2635. http://care.diabetesjournals.org/content/27/11/2628.long. Accessed July 1, 2010.
12. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5):1083-1091. http://care.diabetesjournals.org/content/28/5/1083.long. Accessed July 1, 2010.
13. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436-447.
14. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatideversus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559-569.
15. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, et al. Liraglutide, a longacting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes [published online ahead of print March 19,2007]. Diabetes Care. 2007;30(6):1608-1610. http://care.diabetesjournals.org/content/30/6/1608.long.Accessed July 1, 2010.
16. Drucker DJ, Buse JB, Taylor K, Kendall D, Trautmann M, Zhuang D, et al. Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. Abstract presented at: American Diabetes Association 68th Annual Scientific Sessions; June 6-10, 2008; San Francisco, CA. Abstract #107-OR.
17. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675-688.
18. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28(1):55-72.
19. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637. http://care.diabetesjournals.org/content/29/12/2632.long. Accessed July 1, 2010.
20. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29(12):2638-2643. http://care.diabetesjournals.org/content/29/12/2638.long. Accessed July 1, 2010
21. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194-205.
22. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611-622.
23. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [published online ahead of print June 8, 2009]. Lancet. 2009;374(9683):39-47.